


ERK-IN-7

Cat. No.:	HY-153350
CAS No.:	2494010-63-6
Molecular Formula:	C ₂₂ H ₂₀ ClN ₇ O ₂
Molecular Weight:	449.89
Target:	ERK
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC ₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively ^[1] .																																				
IC₅₀ & Target	ERK1 5 nM (IC ₅₀)		ERK2 7 nM (IC ₅₀)																																		
In Vitro	<p>ERK-IN-7 (Example 10; 24 h) inhibits Colo205 proliferation with an IC₅₀ of 62 nM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="5">Colo205</td> </tr> <tr> <td>Concentration:</td> <td colspan="5"></td> </tr> <tr> <td>Incubation Time:</td> <td colspan="5">24 h</td> </tr> <tr> <td>Result:</td> <td colspan="5">Inhibited proliferation with an IC₅₀ of 62 nM.</td> </tr> </table>						Cell Line:	Colo205					Concentration:						Incubation Time:	24 h					Result:	Inhibited proliferation with an IC ₅₀ of 62 nM.											
Cell Line:	Colo205																																				
Concentration:																																					
Incubation Time:	24 h																																				
Result:	Inhibited proliferation with an IC ₅₀ of 62 nM.																																				
In Vivo	<p>ERK-IN-7 (Example 10; 2 mg/kg; i.g.) shows good pharmacokinetic results^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="5">C57 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td colspan="5">2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td colspan="5">Intragastric administration (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td colspan="5">Pharmacokinetic parameters^[1]</td> </tr> <tr> <td></td> <td>C_{max} (ng/mL)</td> <td>AUC (ng·h/mL)</td> <td>T_{1/2} (h)</td> <td>MRT (h)</td> <td>CL_{Z/F} (mL/min/kg)</td> <td>V_{Z/F} (mL/kg)</td> </tr> </table>						Animal Model:	C57 mice ^[1]					Dosage:	2 mg/kg					Administration:	Intragastric administration (Pharmacokinetic Analysis)					Result:	Pharmacokinetic parameters ^[1]						C _{max} (ng/mL)	AUC (ng·h/mL)	T _{1/2} (h)	MRT (h)	CL _{Z/F} (mL/min/kg)	V _{Z/F} (mL/kg)
Animal Model:	C57 mice ^[1]																																				
Dosage:	2 mg/kg																																				
Administration:	Intragastric administration (Pharmacokinetic Analysis)																																				
Result:	Pharmacokinetic parameters ^[1]																																				
	C _{max} (ng/mL)	AUC (ng·h/mL)	T _{1/2} (h)	MRT (h)	CL _{Z/F} (mL/min/kg)	V _{Z/F} (mL/kg)																															

ERK-IN-7 (Example 10)	1023	3441	3.66	3.47	9.69	3067
-----------------------------	------	------	------	------	------	------

REFERENCES

[1]. Xin Li, et al. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine. Patent WO2020200069A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA